SCHEMBL10240025

SCHEMBL10240025

C[C@@H](O)C(=O)N1CCC(c2nc3c(-c4ccc(-c5ccsc5)nc4)cnn3c(N)c2C=O)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 6/20 0.41
CCNA2 P20248 6/20 0.41
CDK2 P24941 6/20 0.41
CCNA1 P78396 6/20 0.41
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
KDR P35968 3/20 0.36
MTOR P42345 6/20 0.34
RPTOR Q8N122 2/20 0.34
MLST8 Q9BVC4 2/20 0.34
NEK2 P51955 1/20 0.33
PIK3CA P42336 3/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CG P48736 1/20 0.33
LCK P06239 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10234813 0.89 CHEK1 (0.42) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL10234869 0.89 CHEK1 (0.41) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL10240026 0.89 RAB9A (0.37) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL10240078 0.87 MTOR (0.43) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL7881551 0.87 CHEK1 (0.42) CHEK1CCNA2CDK2CCNA1KDR
SCHEMBL10240027 0.87 MTOR (0.35) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL10240086 0.86 NPC1 (0.37) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL7886260 0.86 CHEK1 (0.40) CHEK1CCNA2CDK2CCNA1NPC1
SCHEMBL10240089 0.86 MTOR (0.36) CHEK1CCNA2CDK2CCNA1SMN1; SMN2
SCHEMBL10240075 0.86 MTOR (0.35) CHEK1CCNA2CDK2CCNA1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR CHEK1 461/4885CCNA2 2476/4885CDK2 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.